By the mid-1990s, the Society had experienced significant changes and growth, including a new constitution and bylaws, a newly established scientific structure, and many enhancements in the Annual Meeting. A new generation of leadership had emerged that had only known the post-merger Society. In 1998, the first ASCPT Strategic Plan was created under the leadership of Carl Peck, MD, and ASCPT again found itself going through a variety of changes including:
- In 1999, Sharon Swan, CAE, FASAE, was named Executive Director and moved the Society’s office to the Washington D.C. area to enhance communications, involvement, and visibility. The ASCPT office was later purchased in September 2003 and has since undergone extensive renovations to accommodate the growing needs of the Society.
- ASCPT purchased Clinical Pharmacology & Therapeutics in 2001, and in 2006, Scott A. Waldman, MD, PhD, was selected as Editor-in-Chief of the journal. Under Dr. Waldman’s leadership, the journal transitioned to publisher John Wiley & Sons, selected a new editorial team and added new content and color to the journal. In 2019 Clinical Pharmacology & Therapeutics underwent a leadership transition when Scott Waldman, MD, PhD, completed a more than decade-long editorship of the journal and Piet H. van der Graaf, PhD, PharmD, was named the new Editor-in-Chief and appointed a new team of associate editors.
- In 2012 ASCPT launched the online only Open Access journal CPT: Pharmacometrics & Systems Pharmacology under the leadership of Editor-in-Chief, Piet H. van der Graaf, PhD, PharmD. In 2019 France Mentré, PhD, was appointed the new Editor-in-Chief of the journal.
- In 2016 ASCPT began publishing the online-only Open Access journal Clinical and Translational Science as part of its publication family under the leadership of Editor-in-Chief, John A. Wagner, MD, PhD.
- In 2021, ASCPT released a statement that reaffirms the Society’s commitment to fostering an environment of Diversity, Equity.
- In 2022 Sharon Swan, CAE, FASAE, retired as Chief Executive Officer of the Society after 24 years of service and ASCPT welcomed Abigail. W. Gorman, MBA, as its new Chief Executive Officer in January 2023
A new 2020-2025 Strategic Plan
is in place that focuses on the five strategic goals of enhancing career growth, stimulating scientific advancements, expanding patient-focused engagement, diversifying learning experiences, and providing exemplary value. ASCPT’s program structure is dynamic, ambitious, and field-tested. Its leadership is vibrant and open to new ideas and spheres of influence. The Society’s membership grows yearly and is increasingly diversified. The Society continues to grow internationally as well as within the United States.